Engineered electrical signals, delivered by earbuds, help the brain regain control of immune
function by modulating neurological pathways.
Engineered electrical neural signaling, delivered by earbuds, target neurological pathways that help control immune response
Nēsos is a clinical stage company developing disease modifying digital therapeutics targeting the autonomic nervous system’s control of the immune response. Nēsos clinical efforts are in inflammatory mediated diseases with a current focus on autoimmune, neurological and neuropsychiatric disorders.
Konstantinos Alataris PhD, the founder and former CEO of Nevro (NYSE: NVRO), and a team of neuroscientists and engineers that have developed neurostimulation based therapeutics for neurological disorders are the founding team of Nēsos. Nevro under Konstantinos' leadership advanced Senza®, its implantable neuromodulator therapeutic, from concept to commercialization for chronic pain, subsequently expanding its approved indications.
Nēsos is critically supported by expert clinical and scientific collaborators from leading academic institutions, including Stanford, Vall d'Hebron, Harvard, Mount Sinai, Feinstein Institute, University Of California, San Diego (UCSD), and the University Of California, San Francisco (UCSF).
EULAR 2020 Poster
ACR 2020 Oral presentation by Matt Baker MD (Stanford)
What If You Could Change Your Immune System By Wearing Earbuds? Meet The Startup That Could Make It Possible
Nēsos aims to treat diseases, by restoring neurological pathways that control immune function. Using engineered electrical signals delivered by a noninvasive brain interface. Nēsos is guided and supported by clinical and scientific collaborators from top academic institutions, including Stanford, Vall d'Hebron, Harvard, Mount Sinai, Feinstein Institute, University of California, San Diego, and University of California, San Francisco. For more information, visit www.nesos.com.